SCHEMBL4676986

SCHEMBL4676986

O=C(C=C(O)c1nc[nH]n1)c1cc(COc2ccccc2)n(Cc2ccccn2)c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP10 Q53GL7 1/20 0.36
KDM4E B2RXH2 2/20 0.35
ALDH1A1 P00352 2/20 0.34
TDP1 Q9NUW8 1/20 0.34
KDM4C Q9H3R0 1/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
BRD4 O60885 1/20 0.34
ADRA1D P25100 1/20 0.33
SLC22A12 Q96S37 1/20 0.33
ALKBH1 Q13686 1/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
GPR132 Q9UNW8 1/20 0.33
HDAC3 O15379 1/20 0.32
HDAC4 P56524 1/20 0.32
HDAC1 Q13547 1/20 0.32
HDAC7 Q8WUI4 1/20 0.32
HDAC2 Q92769 1/20 0.32
HDAC10 Q969S8 1/20 0.32
HDAC11 Q96DB2 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4673403 0.91 BRD4 (0.35) KDM4EALDH1A1KDM4CMEN1KMT2A
SCHEMBL4672131 0.88 ERCC5 (0.36) PARP10KDM4EALDH1A1KDM4CMEN1
SCHEMBL4677748 0.87 ALKBH1 (0.35) KDM4EALDH1A1TDP1MEN1KMT2A
SCHEMBL4674862 0.85 ALDH1A1 (0.36) PARP10KDM4EALDH1A1TDP1KDM4C
SCHEMBL4674731 0.85 KDM4E (0.40) KDM4EALDH1A1KDM4CMEN1KMT2A
SCHEMBL4674681 0.83 KDM4C (0.39) KDM4EALDH1A1KDM4CMEN1KMT2A
SCHEMBL4676963 0.82 KDM4C (0.41) KDM4EALDH1A1KDM4CBRD4ADRA1D
SCHEMBL4671361 0.80 KDM4C (0.39) KDM4EALDH1A1KDM4CMEN1KMT2A
SCHEMBL4673982 0.80 ALDH1A1 (0.39) KDM4EALDH1A1TDP1BRD4SMN1; SMN2
SCHEMBL4676863 0.79 KDM4E (0.34) KDM4EALDH1A1KDM4CMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
CN-1335834-A Aromatic heterocyclic compounds having HIV integrase inhibitory activity SHIONOGI & CO (JP) 2002-02-13 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 PARP10 1222/4885KDM4E 947/4885ALDH1A1 980/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.